Stop wasting hours on dense SEC filings. Get AI-powered summaries of any SEC Filings in seconds. Understand key insights and risks, fast.
Currently we only process Form 8-K, 6-K, 3, 4, 144, Schedule 13D and Schedule 13G. We will support more forms in the future.
Filter by Form Type:
Industry:Biotechnologyβ
2026-04-02INDP3SINO LION VENTURES Ltd Acquires Significant Stake in Indaptus Therapeutics, Inc.HIGH
On March 19, 2026, Sino Lion Ventures Limited (Reporting Person) entered into a securities purchase agreement to acquire 259,300 shares of Indaptus Therapeutics, Inc.'s Series AAA Convertible Non-Redeemable Preferred Stock. Each preferred share is convertible into 150 shares of the Issuer's common stock. Following the ...
Nano CapBiotechnology
2026-04-02INDP3Yun Yao Acquires Significant Stake in Indaptus Therapeutics, Inc.HIGH
On March 19, 2026, Yun Yao entered into a securities purchase agreement to acquire 196,800 shares of Series AA Convertible Non-Redeemable Preferred Stock and 253,700 shares of Series AAA Convertible Non-Redeemable Preferred Stock from David Elliot Lazar. Each share of Series AA is convertible into 20 shares of common s...
Nano CapBiotechnology
2026-04-02KRRO3Initial Beneficial Ownership Filing for Korro Bio, Inc.HIGH
This filing reports the initial beneficial ownership of Korro Bio, Inc. (KRRO) by Lynx1 Capital Management LP and Weston Nichols. As of March 31, 2026, Lynx1 Capital Management LP, through its investment manager Lynx1 Capital Management LP and its general partner Lynx1 Capital Management GP LLC, holds 1,537,776 shares ...
Micro CapBiotechnology
2026-04-02Korro Bio, Inc.3Initial Beneficial Ownership Filing for Korro Bio, Inc.DuplicateHIGH
This filing reports the initial beneficial ownership of Korro Bio, Inc. (KRRO) by Lynx1 Capital Management LP and Weston Nichols. As of March 31, 2026, Lynx1 Capital Management LP, through its investment manager Lynx1 Capital Management LP and its general partner Lynx1 Capital Management GP LLC, holds 1,537,776 shares ...
Micro CapBiotechnology